JMP and SAS: Technology Behind RBM Analytics - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
JMP and SAS: Technology Behind RBM Analytics

Source: Applied Clinical Trials

In mid-July, the SAS Press Program released a new book titled Risk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP and SAS. The book is written by Richard C. Zink, Principal Research Statistician Developer in the JMP Life Sciences division at SAS Institute. He is currently a developer for JMP Clinical, a software package designed to streamline the review of clinical trial data.

In this blog, Zink discusses how important data quality is, however, “a significant proportion of trial costs in the pharmaceutical industry are associated with the review of trial data. The goal is to maintain high quality data with more efficient review, leveraging statistics and graphics as much as possible.”

The book is geared toward clinical trial teams interested in taking an analytical and proactive approach to data quality and safety to streamline clinical development activities and address shortcomings throughout a study.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here